Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis and With Inadequate Response or Intolerance to Current Conventional Synthetic DMARDs or Tumor Necrosis Factor Inhibitors

Trial Profile

Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis and With Inadequate Response or Intolerance to Current Conventional Synthetic DMARDs or Tumor Necrosis Factor Inhibitors

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Oct 2018

At a glance

  • Drugs Sarilumab (Primary) ; Azathioprine; Chloroquine; Hydroxychloroquine; Leflunomide; Methotrexate; Methotrexate; Sulfasalazine
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms SariPRO
  • Sponsors Sanofi
  • Most Recent Events

    • 10 Oct 2018 Planned End Date changed from 31 Jan 2020 to 31 Jul 2019.
    • 10 Oct 2018 Planned primary completion date changed from 31 Jan 2020 to 31 Jul 2019.
    • 24 Jul 2018 Planned End Date changed from 15 Apr 2019 to 31 Jan 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top